Scarica l'app Stockscreener
96.90
0.05%
0.05
Dopo l'orario di chiusura:
96.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$96.85
Aprire:
$97.35
Volume 24 ore:
681.35K
Relative Volume:
0.60
Capitalizzazione di mercato:
$24.34B
Reddito:
$3.26B
Utile/perdita netta:
$-1.45B
Rapporto P/E:
-16.50
EPS:
-5.871
Flusso di cassa netto:
$1.18B
1 W Prestazione:
-1.64%
1M Prestazione:
-6.66%
6M Prestazione:
+6.27%
1 anno Prestazione:
-7.28%
Intervallo 1D:
$96.22
$98.00
Intervallo di 1 settimana:
$96.22
$100.21
Portata 52W:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
96.90 | 24.75B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech CEO sells 39,000 shares. BioNTech stock has a USD 126.00 average target - AD HOC NEWS
BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - TradingView
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
BioNTech SE (CEUX:22UAd)Valuation Measures & Financial Statistics - GuruFocus
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech Balances Breakthrough Cancer Data Against a Messy Founder Split () - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Form 4 BioNTech SE For: 25 September - Investing.com India
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
BNTX Stock Price and Chart — NASDAQ:BNTX - tradingview.com
BioNTech SE (22UA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial - TipRanks
eBay Upgraded, Airbnb Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction - Kalkine Media
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19 - ACCESS Newswire
BioNTech's lung cancer drug outperforms chemo in clinical study - mugglehead.com
BioNTech's Oncology Credibility Test Comes Down to Four Days in Seoul () - aktiencheck.de
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biontech Se Adr Azioni (BNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer |
Sep 25 '26 |
Sale |
98.69 |
27,000 |
2,664,581 |
314,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 24 '26 |
Sale |
98.99 |
39,000 |
3,860,661 |
341,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 23 '26 |
Sale |
99.40 |
30,000 |
2,982,081 |
380,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 22 '26 |
Sale |
100.72 |
46,000 |
4,633,037 |
410,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 21 '26 |
Sale |
97.81 |
33,000 |
3,227,720 |
456,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 17 '26 |
Sale |
98.60 |
34,000 |
3,352,342 |
519,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 18 '26 |
Sale |
96.22 |
30,000 |
2,886,729 |
489,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 15 '26 |
Sale |
96.49 |
34,000 |
3,280,636 |
568,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 16 '26 |
Sale |
96.09 |
15,000 |
1,441,340 |
553,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 11 '26 |
Sale |
96.93 |
45,000 |
4,362,021 |
643,209 |
0.82%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):